Detalles de la búsqueda
1.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
2.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656799
3.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499244
4.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559051
5.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Br J Haematol
; 185(3): 450-467, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30729512
6.
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Biol Blood Marrow Transplant
; 22(6): 1009-1016, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26827659
7.
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Health Qual Life Outcomes
; 12: 35, 2014 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-24618388
8.
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study.
Support Care Cancer
; 22(2): 417-26, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24122403
9.
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Haematologica
; 100(8): e311-4, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25769539
10.
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
; 6(12): e616-e629, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31624047
11.
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Haematologica
; 91(6): 862-3, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16769594
12.
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Lancet Haematol
; 3(7): e340-51, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27374467
13.
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
J Clin Oncol
; 28(10): 1749-55, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20194866
Resultados
1 -
13
de 13
1
Próxima >
>>